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Abstract
Background: Neuroinflammation can modulate brain development; however, the influence of an acute peripheral
immune challenge on neuroinflammatory responses in the early postnatal brain is not well characterized. To address
this gap in knowledge, we evaluated the peripheral and central nervous system (CNS) immune responses to a mixed
immune challenge in early postnatal rats of varying strains and sex.
Methods: On postnatal day 10 (P10), male and female Lewis and Brown Norway rats were injected intramuscularly
with either a mix of bacterial and viral components in adjuvant, adjuvant-only, or saline. Immune responses were
evaluated at 2 and 5 days post-challenge. Cytokine and chemokine levels were evaluated in serum and in multiple
brain regions using a Luminex multiplex assay. Multi-factor ANOVAs were used to compare analyte levels across
treatment groups within strain, sex, and day of sample collection. Numbers and activation status of astrocytes and
microglia were also analyzed in the cortex and hippocampus by quantifying immunoreactivity for GFAP, IBA-1, and
CD68 in fixed brain slices. Immunohistochemical data were analyzed using a mixed-model regression analysis.
Results: Acute peripheral immune challenge differentially altered cytokine and chemokine levels in the serum versus
the brain. Within the brain, the cytokine and chemokine response varied between strains, sexes, and days post-challenge.
Main findings included differences in T helper (Th) type cytokine responses in various brain regions, particularly the cortex,
with respect to IL-4, IL-10, and IL-17 levels. Additionally, peripheral immune challenge altered GFAP and IBA-1
immunoreactivity in the brain in a strain- and sex-dependent manner.
Conclusions: These findings indicate that genetic background and sex influence the CNS response to an acute
peripheral immune challenge during early postnatal development. Additionally, these data reinforce that the
developmental time point during which the challenge occurs has a distinct effect on the activation of CNS-resident cells.
Keywords: Rat model, Cytokines, Microglia, Astrocytes, Sex differences, Peripheral immune challenge,
Neuroinflammation, Neuroimmune
Background
An acute peripheral immune response can be widely sys-
temic, affecting a variety of tissues and organ systems,
although the tissue-specific response may vary greatly
[1]. For example, peripheral immune stimulation has
been shown to influence neuroinflammatory responses
in the central nervous system (CNS) [2, 3]. Specific ef-
fects seen in the brain following peripheral immune
challenge include global changes in expression of inter-
feron response genes [4] as well as alterations in cell-
specific transcriptional programming, particularly in
microglia [5, 6]. These transcriptional alterations of neu-
roimmune signaling in early life are hypothesized to
result in developmental priming, potentially leading to
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enduring consequences in response to later life expo-
sures (reviewed in [7, 8]). Therefore, it is important to
gain a deeper understanding of the relationship between
peripheral inflammation and early postnatal CNS
response, to evaluate the risk factors in early life as well
as identify strategies to limit adverse effects.
Under physiologic conditions, immune signaling
within the CNS is coordinated primarily by resident cells
such as microglia, astrocytes, and mast cells due to
tightly regulated infiltration of peripheral leukocytes into
the brain parenchyma [9, 10]. When activated, these
resident immune cells secrete a range of cytokines, che-
mokines, and other regulatory factors that drive neuroin-
flammatory responses and contribute to normal
neurodevelopment and functional homeostasis [11, 12].
Integration of systemic immune signals by CNS-resident
cells may occur via coordinated signaling through the
autonomic nervous system and the hypothalamic-
pituitary-adrenal (HPA) axis [13], trafficking and effector
functions of immune cells within the meninges [14], and
gut microbe-mediated mechanisms [15]. Each of these
systems undergoes overlapping periods of development
and refinement during the first few weeks following
birth. Therefore, immune activation during these critical
periods of development can have broad implications on
neurodevelopment and neural function later in life.
In this study, we focused on understanding the rela-
tionship between the peripheral immune system and
developing CNS by evaluating the respective immune re-
sponses to an acute peripheral, mixed immune challenge
at an early postnatal time point. To do this, we chal-
lenged rats with either a mix of bacterial and viral com-
ponents in adjuvant, adjuvant alone, or saline on
postnatal day 10 (P10). The time point of P10 was
chosen for exposure as it roughly translates to the first
year of life in humans [16, 17] and represents an age of
peak brain growth in rats [18]. We then evaluated the
subsequent peripheral and CNS immune response 2 and
5 days later to compare early vs. late post-challenge im-
mune responses. As a readout, we analyzed cytokine and
chemokine levels in the serum as well as cortical, hippo-
campal, and cerebellar lysates. Additionally, we assessed
the numbers and activation profiles of microglia and as-
trocytes within the cortex and hippocampus. Given the
inherent heterogeneity in the immune response due to
genetic background and sex [19, 20], an additional aim
of the study was to compare the CNS and peripheral im-
mune response following immune challenge in male and
female Lewis and Brown Norway (BN) rats. These
strains of rats were chosen as they exhibit immune re-
sponse skewing, with Lewis rats skewing toward a T
helper (Th) 1 cell (cellular, proinflammatory) response
and BN rats skewing toward a Th2 (humoral, regulatory)
response [21, 22]. While evidence exists suggesting sex-
specific differences in CNS immune responsiveness dur-
ing early postnatal development [23], the influence of
genetic background on sex-specific immune responses is
not as well documented. Therefore, a primary goal of
this study was to identify potential differences in the
region-specific CNS immune response in neonatal rats
to a peripheral mixed immune challenge in the context
of sex and genetic background.
Methods
Materials
The mixed acute peripheral immune challenge was com-
prised of hepatitis B (HepB) (Recombivax HB; Merck &
Co., Whitehouse Station, New Jersey), diphtheria and
tetanus toxoids and acellular pertussis (DTap) (DAPTA-
CEL; Sanofi Pasteur, Swiftwater, Pennsylvania), Hae-
mophilus influenza type b (Hib) (PedvaxHIB; Merck &
Co., Inc., Whitehouse Station, New Jersey), pneumococ-
cal conjugate (PCV) (Prevnar 13; Wyeth Pharmaceuticals
Inc., Madison, New Jersey), and inactivated poliovirus
(IPV) (IPOL; Sanofi Pasteur, Swiftwater, Pennsylvania) in
adjuvant. To match the adjuvant pre-mixed with the
above antigen preparations, a control adjuvant of 2%
aluminum hydroxide gel (Alhydrogel) was obtained from
InvivoGen (San Diego, California).
Animals
All animals were housed in facilities fully accredited by
AAALAC International, and all studies were performed
with regard to the alleviation of pain and suffering under
protocols approved by the University of California-Davis
Institutional Animal Care and Use Committee. Lewis
and Brown Norway (BN) timed-pregnant female rats
(n = 6 per strain) were obtained from Charles River La-
boratories (Portage, MI). Rats were individually housed
on a 12:12-h light:dark cycle at 22 ± 2 °C with food and
water available ad libitum. Lewis dams delivered litters
of 10–12 pups on average, whereas BN dams delivered
litters of 3–5 pups on average. On P7, littermates from
each strain were sexed, randomly assigned to different
experimental groups using a random number generator,
and ear punched for identification purposes.
Peripheral immune challenge
To trigger a full-spectrum innate and adaptive immune
response, we utilized a peripheral immune challenge that
included both bacterial and viral immune-stimulating
agents. Offspring were injected intramuscularly (i.m.) on
P10 with one of the following: acute peripheral immune
challenge in adjuvant, adjuvant mixed with saline, or sa-
line alone. The dose (0.105 μL/g) was determined based
on the human dosing for this antigen mixture and ad-
justed for the average pup weight (approximately 20 g).
Adjuvant control animals were treated with a 1:1
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solution of Alhydrogel and saline, while saline controls
were injected with an equal volume of 0.9% sterile saline.
All treatments were brought up in sterile saline to reach
a final total volume of 25 μL and were administered i.m.
to the vastus lateralis muscle using a sterile 25-gauge
needle. After treatment, pups were returned to their
home cage where they remained with their dam for 2 or
5 days post-injection until they were euthanized for tis-
sue collection.
Blood and brain tissue collection
On P12 or P15, animals were deeply anesthetized with
4% isoflurane in oxygen. Blood samples were then col-
lected via cardiac puncture followed immediately by
transcardial perfusion with sterile phosphate-buffered sa-
line (PBS). Blood was centrifuged (12,000×g, 4 °C, 10
min) to obtain serum, which was then stored at − 80 °C.
Whole brains of animals randomly chosen for cytokine
measurement analyses were quickly removed following
transcardial PBS perfusion and, using a dissection scope
and sterile surgical equipment, microdissected in PBS on
ice to isolate the hippocampi, cortices, and cerebella. All
tissues were snap-frozen in liquid nitrogen and stored at
− 80 °C until further assayed. Animals randomly chosen
for immunohistochemical analyses were anesthetized
with 4% isoflurane in oxygen and subsequently perfused
transcardially with 100-ml cold PBS at a rate of 15 ml/
min using a Masterflex peristaltic pump (Cole Parmer,
Vernon Hills, IL) followed by 100 ml of cold 4% parafor-
maldehyde (PFA) in PBS. Fixed tissues were removed,
post-fixed in 4% PFA overnight, and then stored in 30%
sucrose in PBS at 4 °C for 48 h. Fixed brains were snap-
frozen in O.C.T. Compound (Sakura Finetek, Torrance,
CA) and then sectioned into 10-μm-thick sagittal sec-
tions. Sections were stored at − 80 °C until further proc-
essed for immunohistochemical analyses.
Cytokine and chemokine measurement
Prior to cytokine measurement, brain tissue samples
were thawed and lysed in Bio-Plex cell lysis buffer con-
taining protease and phosphatase inhibitors (Bio-Rad La-
boratories, Hercules, California) and supplemented with
500 mM protease inhibitor phenyl-methylsulfonyl fluor-
ide (PMSF; Sigma-Aldrich, St. Louis, Missouri). Briefly,
tissues were homogenized in 200 μL (hippocampus) or
500 μL (cortex and cerebellum) of cell lysis solution
using a polytron homogenizer for 10 s. The homogenate
was then frozen for 10 min at − 80 °C, thawed, sonicated
for 3 min, and then centrifuged at 4500 g for 4 min. Pro-
tein was quantified in the supernatant using Pierce BCA
assay (Thermo Scientific; Rockford, Illinois), and samples
were stored at − 80 °C until further analyzed.
Concentrations of 10 cytokines and chemokines were
determined using a commercially available multiplex
magnetic bead-based kit (Bio-Plex Pro™ Cytokine Re-
agent Rat Cytokine Assay; Bio-Rad Laboratories,
Hercules, California) in accordance with the kit-specific
protocols provided by Bio-Rad. The following cytokines
and chemokines were measured: granulocyte macro-
phage colony-stimulating factor (GM-CSF), interferon
gamma (IFN-γ), interleukin-1α (IL-1α), IL-1β, IL-4, IL-6,
IL-10, IL-17, monocyte chemotactic protein-1 (MCP-1),
and tumor necrosis factor α (TNF-α). Briefly, lyophilized
rat cytokine standards were first reconstituted with ei-
ther cell lysis buffer (brain samples) or the kit-provided
standard diluent (serum samples), and a standard dilu-
tion series was made. Homogenized brain samples were
run in duplicate at 1 mg/mL, whereas serum samples
were run neat. Fifty microliters of samples, standards,
and corresponding buffer blanks were incubated on a
plate shaker at room temperature (RT) with antibody-
coupled magnetic beads for 1 h. After a series of washes,
biotinylated detection antibodies were added and incu-
bated on a shaker at room temperature for 30 min. The
reaction mixture was detected by the addition of
streptavidin-phycoerythrin following a wash step and in-
cubated on a plate shaker at room temperature for 10
min. Following a repeat of the washing step, beads were
re-suspended in assay buffer for 30 s at room
temperature on the plate shaker. Plates were read on a
Bio-Plex 200 system (Bio-Rad Laboratories, Hercules,
CA, USA) and analyzed using Bio-Plex Manager soft-
ware (Bio-Rad Laboratories) with a five-parameter model
used to calculate final concentrations and values
(expressed in pg/mL). Reference samples were run on
each plate to determine assay consistency. All wash steps
were performed at room temperature using a Bio-Plex
handheld magnetic washer (Bio-Rad Laboratories).
Immunohistochemistry (IHC)
Sections were immunostained for glial fibrillary acidic
protein (GFAP; 1:1000 dilution; Cell Signaling Technol-
ogy, Danvers, Massachusetts), ionized binding adaptor
protein 1 (IBA-1; 1:500 dilution; Wako Bioproducts,
Richmond, Virginia), and CD68 (1:200 dilution; Serotec;
Raleigh, NC). Antibody-antigen complexes were visual-
ized using secondary antibodies labeled with Alexa
Fluor 488, 568, or 647 (Molecular Probes; Eugene, OR),
and slides were mounted in media containing 4′,6-dia-
midino-2-phenylindole (DAPI; Invitrogen, Carlsbad,
CA) to identify cell nuclei. Images of the anterior cin-
gulate (cortex) and dentate gyrus (hippocampus) were
captured automatically by the ImageXpress Micro
Widefield High Content Screening System (Molecular
Devices, Sunnyvale, California) using thresholds set
using region-matched saline controls. Images were ac-
quired in an unbiased manner using the DAPI channel
for each region. Average fluorescence intensity of the
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target antigen, as well as the number of GFAP immu-
nopositive cells or the number of total IBA-1 immuno-
positive cells and percentage of IBA-1 immunopositive
cells also immunopositive for CD68, was quantified
from five fields per region of interest from three serial
sections per brain for a total of 15 microscopic fields
per brain. These values were averaged within a given
animal for each brain region. A total of 3–5 animals
were imaged per group.
Experimental design and statistical analysis
Experimental groups were randomized. Different pups
were used for cytokine analyses versus immunohisto-
chemical analyses, and animals were randomly assigned
to an outcome measure (cytokine measurement or im-
munohistochemistry) and day of collection (2 or 5 days
post-challenge) prior to euthanasia. A total of 93 Lewis
and 90 BN male and female offspring were included in
this study (Luminex: 51 Lewis and 48 BN; IHC: 42 Lewis
and 42 BN).
To assess cytokine levels, statistical analyses were per-
formed using SPSS software (SPSS Version 22; IMB
Corp., Armonk, NY); p values < 0.05 for two-tailed tests
were considered statistically significant. Data graphs
were created using GraphPad Prism (Version 6; Graph-
Pad Software Inc., La Jolla, CA); all results are presented
as mean ± SEM. All data were first assessed for the de-
tection of outliers using the ROUT method, with Q set
to 1%. As the distribution of the cytokine and chemo-
kine concentration values were skewed, natural log
transformations were used in order to approximate nor-
mality. For all values that were below the limit of detec-
tion (LOD), we assigned a value of LOD/2 prior to log
transformation. A preliminary five-way ANOVA was
conducted to determine the effects of sample type (cor-
tex, cerebellum, hippocampus, or serum), cytokine/che-
mokine, treatment, offspring sex, and day of collection
(P12 or P15). The initial five-way ANOVA results led us
to run separate ANOVAs for each sample type and cyto-
kine, as significant source × cytokine effects and interac-
tions were noted for all variables. Therefore, individual
three-way ANOVAs were conducted for each cytokine/
chemokine and sample type, examining the effects of
treatment, offspring sex, and day of collection on levels
of cytokine/chemokines in each sample type. All post
hoc pairwise comparisons of significant interactions
within these three-factorial ANOVAs were Sidak-
adjusted for multiple comparisons.
For IHC analyses, primary outcomes included average
GFAP intensity, total GFAP count, number of IBA-1+
cells, and percentage of IBA-1+ cells co-labeled for CD68
in the hippocampus and cortex for each animal. Mixed-
effects regression models, including animal-specific ran-
dom effects, were used to assess the differences between
three groups of animals (mixed immune, adjuvant, and sa-
line) across the brain regions. Exploratory analysis indi-
cated that a natural logarithmic transformation was
needed for all outcomes other than colocalization to
stabilize the variance and meet the underlying assump-
tions of the mixed-effects models. Due to zeroes for some
outcomes, all values in those outcomes were shifted by 0.1
prior to taking the natural logarithm. Due to a high per-
centage of zeroes, colocalization was dichotomized to 0 or
1 (colocalization > 0) and a repeated measures logistic re-
gression model was used. Day post-immunization (2 or 5),
group (mixed immune, adjuvant, or saline), sex (male or
female), and brain region (cortex, hippocampus) were all
variables of interest in the models. Total cell count was in-
cluded in all models as a covariate. Interactions between
these variables were also considered. Akaike information
criterion was used for model selection and Wald tests for
comparing groups were used. Results for all outcomes
other than colocalization are presented as geometric mean
ratios between the immune challenge or adjuvant groups
and the saline group. All IHC analyses were conducted
using SAS version 9.4. Due to aspects of limited group
numbers and the presence of numerous conditions, statis-
tical comparisons between specific groups (i.e., strain)
were not directly performed but were reported in parallel
to relate findings.
Results
Sex- and region-specific differences in CNS cytokine
expression at baseline
Immune signaling is important for early development,
and sex-specific differences have been evidenced in per-
ipheral and CNS immune signaling under normal condi-
tions [20]. Therefore, we wanted to examine whether
cytokine levels exhibited sex-specific differences at base-
line, under saline control conditions, during early post-
natal development in Lewis and BN rat strains. To
evaluate this, and all subsequent cytokine comparisons,
we used a bead-based Luminex assay to assess the levels
of a set of 10 analytes including a subset of Th-related
cytokines, specifically IFN-γ, IL-4, IL-17, and IL-10, as
well as inflammatory chemokines in peripheral blood
and within different brain regions of experimental ani-
mals. Animals were exposed to peripheral immune chal-
lenge in adjuvant, adjuvant-only, or saline on P10, and
samples were collected 2 and 5 days post-challenge in
male and female Lewis and BN rats (Fig. 1a). Data pre-
sented for baseline sex comparisons were collapsed be-
tween both time points of collection, P12 and P15, as no
statistically significant differences were observed be-
tween the two time points for saline control conditions.
Notable sex-specific differences in baseline cytokine
levels were seen in the cortex and to a lesser extent the
hippocampus. In the cortex, baseline sex differences
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were observed in several important Th-type cytokines,
such as IL-4 (p < 0.001), IL-10 (p = 0.01), and IL-17 (p <
0.05) as well as IL-β (p < 0.001), with males exhibiting
an increased level of these cytokines compared to fe-
males (Fig. 1b). Interestingly, these results were only true
for Lewis rats and not observed in the BN rat strain,
with the exception of higher IL-1β (p < 0.001) in male
BN rats compared to females. When considering cyto-
kine levels in the hippocampus, baseline sex-specific ef-
fects were more limited. Similar to the cortex, a
significant difference was observed for IL-1β (p = 0.01)
in Lewis rats. Additionally, a sex-specific increase in
IFN-γ (p < 0.05) was also seen in the hippocampus of
Lewis rats, with males displaying a higher level of IFN-γ
than females (Fig. 1b).
Minimal sex-specific differences were seen in serum
cytokine levels at baseline, with the only significant
finding being an effect of sex on the level of MCP-1
(monocyte chemoattractant protein 1) in Lewis rats,
with males displaying a greater level of MCP-1 than
females (p = 0.004; Additional file 1: Figure S1A). No
sex-specific differences were observed in the cerebellum
under saline control conditions (Additional file 1:
Figure S1D). In multiple brain regions, baseline differ-
ences in GM-CSF levels were noted but data were not
included in the final analysis due to several samples
having values below the LOD, thus skewing group dif-
ferences (Additional file 1).
Brain region-specific differences in the level of sev-
eral cytokines were also noted. In serum, levels of the
majority of analytes were found to be significantly dif-
ferent than concentrations of these same cytokines
measured in brain regions of the corresponding
animals (Fig. 1c). Specifically, the levels of MCP-1
(p < 0.001), IL-1β (p < 0.001), IL-4 (p < 0.001), and
IL-17 (p < 0.001) were observed to be higher in serum
than the cortex, hippocampus, and cerebellum, while
the level of IL-10 (p < 0.001) appeared lower in the
serum compared to selected brain regions (Fig. 1c).
Differences were also observed when comparing cyto-
kine levels between brain regions with main findings in-
cluding lower levels of many analytes in cortical lysates.
Fig. 1 Sex- and region-specific differences in cytokine levels at baseline. Lewis and Brown Norway (BN) rats were injected i.m. with mixed
immune challenge, adjuvant-only, or saline on P10. Samples were collected 2 or 5 days post-challenge and subjected to cytokine and chemokine
profiling. a Illustration of experimental design with primary outcome measures. b, c Cytokine and chemokine levels under saline control
conditions. b Cytokine levels compared within strains (BN (15; 6M, 9F), Lewis (15; 7M, 8F)) and between sexes; collapsed between time point of
collection due to no differences observed. c Cytokine levels compared across region of collection; collapsed between sex, strain, and day of
collection. N = 30 animals per region. Star (*) corresponds to comparisons between serum and all brain regions using the following scale: *p <
0.05, **p < 0.01, ***p < 0.001. Hashtag (#) represents comparisons solely between brain regions only using a similar scale. B.D. defined as below
detection. All data are displayed as the natural log-transformed values with mean +/− SEM
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The levels of IL-1α (p < 0.001), IL-1β (p < 0.001), IFN-γ
(p < 0.001), IL-4 (p < 0.001), and IL-6 (p < 0.001) were
seen to be lower in the cortex, compared to both the
hippocampus and cerebellum (Fig. 1c), while IL-10 (p <
0.05) was significantly lower in the cortex compared to
the hippocampus only, and cortical IL-17 (p < 0.001) was
less than that measured in the cerebellum. Additionally,
the hippocampal level of TNF-α was significantly lower
in the hippocampus compared to other brain regions
(p < 0.001; Fig. 1c).
Effect of peripheral immune challenge on serum
cytokines and chemokines
Next, to broadly characterize the innate and adaptive im-
mune responses to an early postnatal peripheral immune
challenge, we assessed post-challenge cytokine levels be-
tween strain, sex, region, and time point of collection as de-
scribed above and outlined in Fig. 1a. Consistent with the
age of the rat pups, the effect of treatment on the serum
cytokine response was relatively mild (Additional file 2: Fig-
ure S2A and Additional file 3: Figure S3A). Over half of the
serum samples had levels of IFN-γ, IL-1α, IL-6, and TNF-α
below the LOD, and these cytokines were therefore ex-
cluded from further analysis. For serum analytes that were
above the LOD and were found to be differentially regu-
lated in response to treatment, effects were broadly similar
across strains with some sex-specific skewing. For GM-
CSF, significant main effects of treatment were seen in both
Lewis and BN rat strains (Additional file 2: Figure S2A).
Specifically, post hoc testing revealed sex-dependent in-
creases in the level of GM-CSF in serum 5 days post-
challenge in males of both strains (Lewis, p < 0.001; BN,
p = 0.005; Fig. 2a), with significant increases also seen under
adjuvant conditions in male Lewis rats (p = 0.001). In con-
trast, female BN rats exhibited significant increases in GM-
CSF in response to adjuvant treatment compared to saline
controls at the same time point (p < 0.001; Fig. 2a). Of note,
a significantly higher level of GM-CSF was seen under adju-
vant conditions compared to immune challenge in female
BN rats at 5 days post-challenge (Fig. 2a). However, this
was the only instance of such a finding in the study and is
likely due to several serum GM-CSF values falling below
the level of detection in these animals. A main effect of
treatment was observed in the level of the chemokine
MCP-1 in both Lewis and BN rats (Additional file 2: Figure
S2A). Higher levels of MCP-1 were detected under
adjuvant-only conditions at 5 days post-challenge in female
BN rats (p = 0.02) and at 2 days post-challenge in female
Lewis rats (p = 0.001), or 2 days following mixed immune
challenge in Lewis males (p = 0.016; Fig. 2b).
Innate immune cell-related cytokine response in the CNS
To understand the CNS immune response to an acute
peripheral immune challenge, we evaluated cytokine and
chemokine levels in tissue lysates from the cortex,
hippocampus, and cerebellum of male and female Lewis
and BN rats. The most striking results and greatest in-
flammatory response to the mixed immune challenge
were seen in the cortex. In both male and female Lewis
and BN rats, a significant main effect of treatment was
observed for several cytokines associated with the innate
immune response in the cortex at 2 and 5 days following
treatment (Additional file 2: Figure S2B). Specifically, IL-
1α, IL-1β, and IL-6 were significantly upregulated
following either peripheral immune challenge or
adjuvant-only exposure in both strains (Fig. 3a). Similar
effects of treatment were noted for GM-CSF and MCP-
1, both important innate immune cell recruitment and
activation molecules (Fig. 3a). Representative cortical in-
nate immune cytokine data are collapsed across sex and
time point of collection as a response to treatment ap-
peared similar between these conditions. The only ex-
ception to this pattern was the lack of increased MCP-1
expression in the cortex in male BN rats exposed to ei-
ther peripheral immune challenge or adjuvant-only
(Additional file 3: Figure S3B).
In the hippocampus, a main effect of treatment was also
seen for the majority of cytokines (Additional file 2: Figure
S2C). A significant increase in GM-CSF compared to saline
controls was observed at both 2 and 5 days post-challenge
across experimental conditions, strains, and sexes (Fig. 3b,
Additional file 3: Figure S3C). In both sexes, significant in-
creases in IL-1α (p < 0.05) and IL-1β (p < 0.001) were noted
in BN rats, while a significant increase in IL-1β (p < 0.001),
but not IL-1α, was observed in Lewis rats at 2 but not 5
days post-challenge (Fig. 3b). Elevated levels of MCP-1 were
seen only in female Lewis rats at 2 days (p = 0.01) and 5
days (p = 0.034) post-challenge (Fig. 3b). Interestingly, im-
mune challenge decreased hippocampal IL-6 relative to sa-
line control in female rats of both strains (p < 0.05; Fig. 3c).
Other cytokines, such as IL-1α and IL-1β, were also de-
creased by peripheral immune challenge or exposure to
adjuvant-only at 5 days post-challenge (Additional file 3:
Figure S3C). The effect of peripheral immune challenge on
the cytokine response in the cerebellum was both weak and
varied (Additional file 2: Figure S2D), with the exception of
a significant increase in GM-CSF, similar to that seen in
the hippocampus and cortex (Additional file 3: Figure S3D).
Th-type cytokine responses in the CNS
Due to evidence suggesting that the immune responses
in Lewis and BN rats are skewed toward a Th1- or Th2-
specific response, respectively [21, 22], a primary aim of
this study was to evaluate the contribution of a different
genetic immune background on the response to immune
challenge. In cortical lysates from both strains, a main
effect of treatment was observed for all canonical Th-
type cytokines measured (Additional file 2: Figure S2B).
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Interestingly, the level of IFN-γ (a major Th1 cytokine)
in the cortex following mixed immune challenge was
significantly elevated in males of both strains (p < 0.001),
with similar effects at 2 and 5 days post-challenge
(Fig. 4a). In female rats of either strain, cortical IFN-γ
levels were significantly increased at 5 days (p < 0.01) but
not at 2 days post-challenge (Fig. 4a). In contrast to the
cortical response, peripheral immune challenge had little
or no significant effect on IFN-γ levels in the hippocam-
pus and cerebellum of Lewis or BN rats (Additional file 3:
Figures S3C and D). Striking strain and sex differences
were seen in the response to immune challenge in cor-
tical levels of IL-4, an indicator of Th2-type responses.
Specifically, peripheral immune challenge significantly
increased cortical IL-4 levels in female Lewis rats at 2
days (p = 0.003) and 5 days (p < 0.001) post-challenge,
while exposure to adjuvant-only treatment only resulted
in elevated cortical IL-4 levels at 5 days post-exposure
(p < 0.001; Fig. 4b). In contrast, compared to saline con-
trols, cortical IL-4 levels were significantly decreased in
female BN rats in response to mixed immune challenge
(p < 0.01) or adjuvant (p < 0.01), or unchanged in male
rats of either strain (Fig. 4b; Additional file 3: Figure
S3B). Coincident with these responses, post hoc analysis
revealed a lack of effect of either immune challenge or
adjuvant-only on IL-17 levels in the BN rat cortex at
both 2 and 5 days post-challenge. However, cortical IL-
17 levels were significantly elevated compared to con-
trols in response to mixed immune challenge in male
Lewis rats (p < 0.001) and in response to either mixed
immune (p < 0.05) or adjuvant treatment (p < 0.05) in
female Lewis rats (Fig. 4c). Cortical IL-10 levels were
similar between strains, although significantly increased
levels of IL-10 in response to experimental manipulation
were seen only in male rats, with no apparent effects in
females (Fig. 4d). Data for cortical IL-17 and IL-10 levels
Fig. 2 Elevated serum cytokines in response to mixed immune challenge or adjuvant. Serum cytokine and chemokine levels of GM-CSF (a) and MCP-1
(b) following immune stimulus represented by day of collection (P12/P15), strain (Lewis/BN), and sex. Data presented as natural log-transformed values
with mean +/− SEM. N = 3–6 animals per condition; *p < 0.05, **p < 0.01, ***p < 0.001
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were collapsed between day of collection due to minimal
differences seen for those two analytes over time
(Additional file 3: Figure S3B).
In the hippocampus, male BN rats exhibited signifi-
cant increases in IFN-γ (p < 0.001), IL-4 (p = 0.035),
IL-10 (p = 0.037), and IL-17 (p < 0.001) in response
to treatment at 2 days post-immune challenge (Fig. 4e).
Interestingly, there were no significant increases in
the levels of these cytokines in the hippocampus of
female BN rats or either sex of Lewis rats (Add-
itional file 3: Figure S3C). While a main effect of treat-
ment on Th-type responses in the cerebellum was
apparent under certain conditions (Additional file 2: Fig-
ure S2D), post hoc analysis revealed effects of treatment
on cytokine production in the cerebellum to be largely
non-significant across most conditions (Additional file 3:
Figure S3D).
Evaluation of CNS cellular immune response
To understand the effects of mixed immune challenge
or adjuvant-only exposure on the brain-specific cellular
response, the number of GFAP immunopositive cells
and the average intensity of GFAP immunofluorescence
were evaluated as indicators of astrogliosis, whereas the
total number of IBA-1 immunopositive cells and per-
centage of IBA-1 immunopositive cells also immunore-
active for CD68 were quantified to assess the microglial
response.
GFAP is an intermediate filament expressed mainly in
astrocytes that is upregulated under conditions of hyper-
trophy and activation [24]. In both the cortex and hippo-
campus, GFAP average fluorescence intensity was
significantly increased within both strains at 2 and 5 days
post-challenge. In Lewis rats, across all conditions, the
average intensity of GFAP immunoreactivity was
Fig. 3 Peripheral immune stimulation broadly upregulates innate cytokine levels in the cortex and hippocampus. Cortical, hippocampal, and
cerebellar lysates were collected from rats 2 or 5 days following exposure and subjected to cytokine and chemokine analysis. a Concentrations of
innate cytokines in the cortex, compared between experimental conditions. Data are collapsed between sex and day due to minimal differences
seen; N = 15–20 per condition. b, c Cytokine levels from hippocampal lysates; black solid bars above certain analytes specify time point or sex-
specific conditions. b Levels of several innate cytokines: GM-CSF collapsed between sex and day (N = 13–20 per condition), IL-1a, IL-1B shown at
P12 only and MCP-1 in females collapsed between day (N = 7–10 per condition). c Hippocampal IL-6 levels across treatment and strain in female
rats; N = 4–5 per condition. Data represent mean +/− SEM, *p < 0.005, **p < 0.01, ***p < 0.001
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significantly higher in the hippocampus than in the cor-
tex, whereas no significant regional differences were ob-
served in BN rats (Fig. 5a–c). In addition to brain
region-specific strain differences, sex-specific effects of
both mixed immune challenge and adjuvant-only expos-
ure on average intensity of GFAP immunofluorescence
were observed. While exposure to either treatment sig-
nificantly increased the average intensity of GFAP im-
munofluorescence in male and female BN rats across
brain regions at 2 and 5 days post-challenge (Fig. 5d), ex-
posure to either treatment in Lewis rats significantly
increased the average intensity of GFAP immunofluores-
cence in males only (Fig. 5e). Due to best-fit statistical
modeling used for IHC analysis, conditions were col-
lapsed between groups when no differences were ob-
served. With regard to GFAP intensity as noted here, a
similar response to immune challenge was seen across
the brain region within a rat strain.
A significant increase in the number of GFAP immu-
nopositive cells was also seen in response to mixed im-
mune challenge or adjuvant-only exposure, but these
effects varied between brain regions and strains. In the
cortex, GFAP immunopositive cell counts were increased
following mixed immune challenge or adjuvant-only ex-
posure in both strains at 2 and 5 days post-challenge
(Fig. 5f, g) with the exception of female BN rats that ex-
hibited no significant change in GFAP immunopositive
cell counts at 2 days post-mixed immune challenge
(Fig. 5g). In contrast, more consistent sex and strain differ-
ences were seen in the hippocampus. In Lewis rats, males
exhibited a significant increase in the number of GFAP
immunopositive cells in the hippocampus 2 and 5 days
post-challenge following mixed immune challenge or
adjuvant-only exposure, whereas female Lewis rats
showed no differences in response to either challenge
(Fig. 5f). In the BN strain, the numbers of GFAP immuno-
positive cells in the hippocampus significantly increased in
both sexes 2 and 5 days post-challenge, with the exception
of male BN rats that exhibited no effect at 5 days post-
challenge (Fig. 5g).
The cellular neuroinflammatory response was further
evaluated by immunostaining for IBA-1 in the cortex
and hippocampus. IBA-1 is a pan-macrophage/monocyte
marker used broadly in the brain to identify microglia
[25]. Interestingly, in contrast to increased brain GFAP
immunofluorescence intensity and number of GFAP
immunopositive cells seen across many conditions, the
number of IBA-1 immunopositive cells in the cortex and
hippocampus were either unchanged or significantly de-
creased in these regions in response to mixed immune
challenge or adjuvant-only exposure, compared to saline
controls (Fig. 6a, b). In BN rats, a reduction in the num-
ber of IBA-1 immunopositive cells was observed in the
cortex and hippocampus of male rats exposed to either
Fig. 4 CNS Th-type responses to peripheral immune stimulation are sex- and strain-specific. Th-type cytokine responses were evaluated in brain
lysates. Cortical IFN-γ; N = 3–6 per condition (a), IL-4; N = 3–5 per condition (b), IL-17; N = 7–11 per condition (c) and IL-10; N = 7–10 per condition
(d) levels. IL-4 displayed only in female rats due to no differences seen in males; IL-10 and IL-17 levels collapsed between day. e Hippocampal
Th-type cytokine levels in male rats at 2 days post-challenge; N = 3–5 per condition. Data represent mean +/− SEM, *p < 0.005,
**p < 0.01, ***p < 0.001
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mixed immune challenge or adjuvant-only and in the
cortex and hippocampus of females treated with
adjuvant-only (Fig. 6b). In contrast, there was no differ-
ence in the number of IBA-1 immunopositive cells in fe-
male BN rats exposed to mixed immune challenge or
Lewis rats under either treatment condition compared
to saline controls (Fig. 6b, c).
Additionally, colocalization of CD68 immunoreactiv-
ity with IBA-1 was used as a measure of microglial acti-
vation in the brain, as CD68 is a lysosomal marker used
broadly to indicate phagocytic activity in macrophages
[26]. Following the analysis of the response to either
mixed immune challenge or adjuvant exposure, there
were no significant differences between treatment
conditions, strain, or sex with respect to IBA-1/CD68
colocalization (Fig. 6d).
Discussion
The physiologic importance of the interplay between the
immune and nervous systems in neurodevelopment has
gained recognition in recent years, and immune mole-
cules are increasingly implicated as important in neuro-
genesis, cortical development, and neurodevelopmental
disorders [27–30]. Despite this, knowledge regarding the
CNS response to a peripheral immune challenge during
early postnatal development is limited in scope. Numerous
Fig. 5 Sex- and strain-specific increases in the average intensity of GFAP immunoreactivity and numbers of GFAP immunopositive cells. GFAP
immunoreactivity was assessed at 2 and 5 days post-exposure. Representative photomicrographs of GFAP immunoreactivity and DAPI labeling in
the cortex (a) of female rats and the hippocampus (b) of male BN and female Lewis rats; Sal=saline, Adj=adjuvant-only, Imm=immune challenge.
c Geometric mean ratio (GMR) of GFAP average intensity in response to immune challenge, adjuvant-only, or saline control conditions in the
hippocampus versus the cortex within each strain; collapsed between sex and day of collection (N = 42 per strain; BN(19Imm, 19Adj, 4Sal);
Lewis(16Imm(8M/8F), 17Adj(9M/8M), and 9Sal(5M/4F)). GMR plots of GFAP average intensity in BN (d) and Lewis (e) rats collapsed between day
and region, as well as GFAP-positive cell counts in Lewis (f) and BN (g) strains of each treatment relative to saline control collapsed between the
day of collection in (f). Error bars represent 95% CI; a CI not including the normalization line (line at 1) indicates a significant difference between
brain regions (c) or the treatment and saline controls (d–g) at p ≤ 0.05
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studies have investigated perinatal immune signaling and
CNS development using iterations of the maternal im-
mune activation (MIA) paradigm (reviewed in [31]). This
is likely due to the growing body of literature on the topic,
clinical relevance, and thorough characterization of the
methodology [32]. Although, recent research has sug-
gested, perhaps unsurprisingly, that MIA-induced effects
on brain circuit-specific function are dissociable from
those effects induced by early postnatal immune chal-
lenge, with contrasting results on glutamatergic and
GABAergic signaling respectively [33]. Therefore, it is of
value to develop a deeper knowledge regarding how acute
peripheral immune stimulation, postnatally, may influence
the production of immune effector molecules and activa-
tion of glial cells in the CNS. The latter point is particu-
larly important as altered neural function due to perinatal
immune activation may depend partly on early glial prim-
ing, contributing to long-term functional alterations in
these cells [5, 6, 30].
An important aspect of our study design is the devel-
opmental window during which the acute mixed im-
mune challenge occurred. Prior studies comparing the
timeline of rat and human development suggest that
preweaning ages in rats correspond to roughly the first
year of life in humans [16, 17]. Therefore, to mirror the
immune challenges a human infant may face in early life,
we chose to expose rats on P10—a time of early postna-
tal development when hematopoiesis is shifted from the
fetal liver and spleen to the bone marrow, and the
lymphoid architecture begins to take shape [34]. Fur-
thermore, in rodent development, P10 is a time shortly
after the early critical period for sexual differentiation of
the brain [35] and represents an age of peak brain
growth in rats [18]. These factors are important for
proper interpretation of sex- and age-specific compari-
sons in this study.
To characterize peripheral and central responses, we
collected serum and brain samples from Lewis and BN
rats at 2 and 5 days post-exposure to immune challenge,
adjuvant-only, or saline. These time points were chosen to
correspond to an early stage, 2 days post-exposure, where
innate immune mechanisms would be dominant, and at a
later stage, 5 days post-exposure, where adaptive immune
responses would potentially be active [36]. Importantly,
development of the adaptive immune system in rodents is
similar to humans in that perinatal lymphocyte numbers
Fig. 6 Minimal effects of treatment on IBA-1 immunoreactivity. The number of IBA-1 immunopositive cells was quantified in the cortex and hippocampus in
response to treatment. a Representative photomicrographs of IBA-1 immunoreactivity and DAPI labeling in the cortex of BN rats; Sal=saline, Adj=adjuvant-
only, Imm=immune challenge. Geometric mean ratio (GMR) plots displaying the number of IBA-1 immunopositive cells for treatment versus saline control in
BN (N= 40; 18Imm(10M/8F), 18Adj(9M/9F), 4Sal(2M/2F) (b), and Lewis (N= 42; 15Imm, 15Adj, 7Sal) (c) rat strains. Data for IBA-1 immunopositive cell counts
expressed as ratio over saline control conditions. Error bars represent 95% CI; a CI not including the normalization line (line at 1) indicates a significant
difference between the treatment and saline controls at p≤ 0.05. d Quantification of IBA-1/CD68 colocalization within strains and across treatment conditions,
data expressed as boxplots illustrating the distribution of data points for each animal and the interquartile range
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and proliferative responses in lymphoid organs are low
[37]. Further evidence suggests that germinal center for-
mation is absent at P10 in rats and, subsequently, they are
thought to be incapable of mounting a proper primary im-
mune response [38]. Therefore, it is not surprising that
many cytokine levels were below the level of detection in
the peripheral blood. However, it is notable that the cyto-
kines IL-4, IL-10, and IL-17 were detectable in serum,
albeit with no significant differences between experimental
groups or rat strain. Relevant here, and known to be simi-
lar between species, evidence shows that early postnatal
Th-type responses in rats and other mammals are skewed
toward Th2 [39, 40]. Furthermore, studies in neonatal
mice using exposure to various inoculation components
resulted in a decreased IgG (immunoglobulin G) 2a/IgG1
ratio compared to similarly exposed adult animals [41].
These data support a bias of a Th2-type versus Th1-type
response during the neonatal period. The inability to de-
tect serum IFN-γ in our samples while observing measur-
able IL-4 and IL-10 levels may lend further credence to
this potential skewing.
In contrast to the modest peripheral response, the
cytokine and chemokine responses within the CNS were
significantly more robust, with the most dramatic effects
noted in the cortex. While the cytokines IL-1α and IL-6
were not detectable in the serum, they were markedly
elevated in the brains of rats of both strains following
the peripheral immune stimulation or adjuvant-only ex-
posure, compared to saline control animals. Of import-
ance, IL-1 and IL-6 are known to modulate glial
responsiveness and are suggested to be crucial for glial
proliferation and the release of important trophic factors
to support brain plasticity [42, 43]. These current data
may support this finding, as male BN rats, which exhib-
ited no significant differences in IL-1 or IL-6 levels in
the hippocampus 5 days post-treatment, also exhibited
no difference in the number of GFAP immunopositive
cells in the same region at the same time point in these
animals. Whereas, at other time points and between
sexes, there were significant differences in relevant cyto-
kine levels and GFAP immunopositive cell numbers. It is
important to note that the relationships described here
and elsewhere regarding glial activation and cytokine
levels are partly speculative as direct comparisons be-
tween GFAP or IBA-1 reactivity and specific cytokines
were not conducted due to the large number of groups
already being compared. Another innate cytokine signifi-
cantly upregulated in the brain within the majority of
treatment groups was GM-CSF, long known as a regula-
tor of macrophage differentiation and more recently
believed to play a role in myeloid cell to lymphocyte
communication [44, 45]. This may suggest expansion or
activation of the resident macrophage population. How-
ever, no significant differences in the number of IBA-1
immunoreactive cells were noted between experimental
conditions and among different brain regions in Lewis
rats, whereas significant decreases in IBA-1 immunopo-
sitive cell numbers were observed in the cortex and
hippocampus of BN rats, with the exception of female
BN rats exposed to mixed immune challenge. MCP-1, a
chemokine important for glial differentiation and motil-
ity [46], was also significantly elevated in response to
treatment. However, the MCP-1 response was sex and
strain-specific, with no observable relationship to
changes in GFAP or IBA-1 immunostaining. Our find-
ings that GM-CSF and MCP-1 levels did not appear to
relate to the immunohistochemical results of CNS cellu-
lar immune activation are surprising due to their puta-
tive role in potentiating glial responses [47]. Possible
explanations for this discrepancy could be the develop-
mental stage of the animals at the time of exposure and
sample collection, or that these molecules may act as
signals to recruit other immune cells to the CNS com-
partment. As limitations in this study, we did not
investigate the possibility of peripheral immune cell infil-
tration in the brain, blood-brain barrier permeability, or
the cellular source of the cytokines/chemokines. These
aspects are certainly important to determine mechanistic
aspects of the immune dysregulation seen but were out-
side the scope of the initial study aims and are definite
points for future investigation.
In support of the concept that cytokine and chemokine
signaling is important for glial regulation and neurodeve-
lopment under normal conditions, levels of most cyto-
kines and chemokines within the CNS of both Lewis and
BN rats were already strikingly high under saline control
conditions. This result appeared across the brain regions
surveyed, with some variation at the level of single ana-
lytes. For example, IL-4, IL-10, and IL-17 were detected at
surprisingly high levels throughout the brain at baseline,
whereas levels of IL-6 were robust in the hippocampus
and cerebellum, yet barely detectable in the cortex. These
findings corroborate previously published data also ob-
serving appreciable levels of cytokines across brain regions
at baseline during early postnatal development and specif-
ically validate outcomes seen in our dataset such as lower
IFN-γ in the cortex compared to the hippocampus in the
second postnatal week [48]. While of interest, the biologic
significance behind this brain region-specific difference in
IFN-γ and other cytokines does not seem to be evident in
the existing literature and will be important for further
study. Additionally, our study suggests that cytokine levels
at baseline appear to vary widely as a function of sex or
strain. These data strongly support previous findings that
immune molecule signaling in the CNS is active during
normal neurodevelopment [49] and suggest consideration
of sex and strain differences in the design of neuroimmu-
nological experiments.
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While innate-like cytokines and chemokines within
the CNS showed broadly similar patterns across strain
and sex, CNS Th-type cytokine responses varied greatly
between Lewis and BN rats. These two rat strains were
chosen for comparison due to previous knowledge of the
susceptibility or resistance of either strain to the devel-
opment of Th-subset specific disorders [50, 51]. How-
ever, the basis of this skewing may not only involve the
CD4+ T cell compartment, but also CD8+ T cells and
mast cells [21, 52, 53]. Given these findings, it may be
anticipated that this immune response skewing could
extend to the CNS as well. Using IFN-γ as a crude
marker of a Th1-type response, our results suggest that
these two strains do not differ greatly in Th1-type re-
sponses within the CNS. However, when evaluating IL-4
levels as a readout of a Th2-type response, the results
were dramatically different. In the cortex, where the
most robust cytokine responses were noted, female
Lewis rats exhibited elevated levels of IL-4 in response
to mixed immune challenge or adjuvant, whereas a sig-
nificant decrease in IL-4 was noted in female BN rats
under the same treatment conditions. No significant
treatment-related differences in the level of IL-4 were
observed in male rats of either strain. These results seem
in opposition of what might be expected with Lewis rats
exhibiting a greater IL-4 response and BN rats showing
no changes or decreases in IL-4 levels in cortical lysates.
However, when considering that we also observed sex
and strain differences in other Th-subtype cytokines, this
outcome suggests several non-mutually exclusive possi-
bilities. First, as supported by the current study, the CNS
cytokine response is likely different than the concomi-
tant peripheral immune response. Second, it could be
that genetic immune skewing between Lewis and BN
strains cannot be classified into a defined Th-subset cat-
egory. Finally, sex may be a greater determinant than
genetic background when considering CNS immune
skewing. Inherent differences in Th1/Th2 skewing be-
tween sexes have been previously proposed, with females
skewed toward a Th2 dominant response [54]. Our data
are consistent with this last point, at least with regard to
IL-4 levels in the CNS.
These cytokine results, coupled with IHC evidence of
significant increases in GFAP reactivity in female BN rats,
may suggest a model in the cortex in which decreased IL-
4 levels are related to astrocytic activation. In support of
this concept, recent work has shown that pretreatment
with IL-4 prior to peripheral LPS exposure abolishes LPS-
induced astrocytic activation in the cortex of mice, as
measured by GFAP immunoreactivity and iNOS expres-
sion [55]. Additionally, under many conditions, IL-4
responses are characterized as anti-inflammatory in nature
and may act as a growth or repair responses in the brain
[56, 57]. Therefore, it is plausible that IL-4 levels in the
brain play an important role in regulating cellular inflam-
matory status, at least in regard to astrocytic activation.
Surprisingly, peripheral immune challenge or adjuvant
exposure alone either had no effect or significantly de-
creased the number of IBA-1 immunopositive cells in
the cortex and hippocampus. Additionally, no significant
effects were noted upon assessment of IBA-1 colocaliza-
tion with CD68. This is interesting as we saw a robust
increase in GFAP immunopositive cells and expression
levels across most conditions. The reasoning for this
could lie once again in the developmental time period of
exposure, as microglia undergo distinctive rounds of
maturation during the perinatal period [58, 59]. In sup-
port of this reasoning, recent work has demonstrated
that peripheral LPS challenge in P14 mice resulted in a
significant increase in GFAP but not IBA-1 reactivity in
the hippocampus [60]. More importantly, opposite ef-
fects were observed when adult animals were subjected
to the same treatment, with pronounced increases in
IBA-1 reactivity but not GFAP reactivity [60]. Further-
more, a separate group found that glial activation oc-
curred sequentially in response to a systemic immune
challenge, with microglial activation occurring shortly
after exposure and induction of astrocytic activation
occurring in a delayed manner [61]. These studies sug-
gest that glial activation is tightly regulated both tempor-
ally and spatially.
Conclusion
The current study supports existing evidence that immune
signaling molecules are highly upregulated in the brain fol-
lowing a peripheral immune challenge. Additionally, it em-
phasizes the influence of factors such as sex and genetic
background on the cytokine and chemokine response, as
well as astrogliosis and microgliosis within the brain. Inter-
estingly, we observed high concentrations of various cyto-
kines in the CNS under baseline conditions, the levels of
which also varied significantly depending on strain, sex, and
brain region. While this study provides a thorough
characterization of the CNS immune response to a periph-
eral immune challenge, taking into account a broad number
of factors, further study is needed to provide mechanistic
support for how this cytokine/chemokine signaling and cel-
lular activation may shape brain development.
Additional files
Additional file 1: Baseline cytokine results. Analysis of cytokine levels in
response to saline-only conditions. Results represent cytokine concentrations
in the serum (A), cortex (B), hippocampus (C), and cerebellum (D) of male
and female Lewis (N=15; 7M, 8F) and BN (N=15; 6M, 9F) rats. Data represent
mean +/- SEM, collapsed between day of collection. Value b.d. represents
analytes where >50% of samples were below the level of detection and
excluded from analysis; *p<0.005, **p<0.01, ***p<0.001. (JPG 1626 kb)
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Additional file 2: Main effect of treatment on cytokine levels. Results of
ANOVA analyses considering a main effect of treatment on cytokine and
chemokine levels in the serum (A), cortex (B), hippocampus (C), and
cerebellum (D) of Lewis and BN rats. Red coloring denotes a significant
finding (p<0.05), while pink coloring represents a trending result (0.05<p<1).
(JPG 1038 kb)
Additional file 3: Total cytokine and chemokine protein analyses of
serum and brain lysates. Multi-factorial ANOVA analyses were conducted;
p-values displayed here reflect Sidak-adjusted values for multiple
comparisons. Tabular results of comparative cytokine and chemokine
analyses between treatment conditions and within day of collection, sex,
and strain; split between results in the serum (A), cortex (B), hippocampus
(C), and cerebellum (D). Tables display statistical analysis of immune
challenge (Imm), adjuvant-only (Adj) and saline (Sal) conditions with
representative colors: red, p<0.05; light red, 0.05<p<0.1; dark blue, p<0.05;
light blue, 0.05<p<0.1. Red coloring overall corresponds initial treatment
conditions over the second in the row; e.g. a red cell in Imm/Sal row is
interpreted as significant increase in Imm compared to Sal for that analyte,
blue cells are the inverse relationship and would represent a decrease in
Imm compared to Sal. A value of b.d. is indicative of cytokine/chemokine
values below the level of assay detection. (JPG 1756 kb)
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